Drugs / Regulatory Donor-Derived Dendritic Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03164265 | Aug 2017 → Jul 2024 | — | Angus W. Thomson PhD DSc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Regulatory Donor-Derived Dendritic Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03164265 ↗ |
| Known as | ddDCreg | “pre-emptive donor-derived DCreg (ddDCreg) infusion” PMID 41997912 ↗ Apr 2026 |
| Modality | Cell therapy | “Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients” NCT03164265 ↗ |